Kodiak Sciences Inc.
KSI-101
neovascular age-related macular degeneration (wet AMD)
Countdown
358days
Phase 3 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 3 trial results for KSI-101 in neovascular age-related macular degeneration (wet AMD) are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Topline results from PEAK are expected in 4Q 2026.”